Literature DB >> 21647780

Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia.

Kamel Rouissi1, Slah Ouerhani, Bechr Hamrita, Karim Bougatef, Raja Marrakchi, Mohamed Cherif, Mohamed Riadh Ben Slama, Mohamed Bouzouita, Mohamed Chebil, Amel Ben Ammar Elgaaied.   

Abstract

Cancer epidemiology has undergone marked development since the nineteen-fifties. One of the most spectacular and specific contributions was the demonstration of the massive effect of smoking and genetic polymorphisms on the occurrence of bladder cancer. The tobacco carcinogens are metabolized by various xenobiotic metabolizing enzymes, such as the super-families of N-acetyltransferases (NAT) and glutathione S-transferases (GST). DNA repair is essential to an individual's ability to respond to damage caused by tobacco carcinogens. Alterations in DNA repair genes may affect cancer risk by influencing individual susceptibility to this environmental exposure. Polymorphisms in NAT2, GST and DNA repair genes alter the ability of these enzymes to metabolize carcinogens or to repair alterations caused by this process. We have conducted a case-control study to assess the role of smoking, slow NAT2 variants, GSTM1 and GSTT1 null, and XPC, XPD, XPG nucleotide excision-repair (NER) genotypes in bladder cancer development in North Tunisia. Taken alone, each gene unless NAT2 did not appear to be a factor affecting bladder cancer susceptibility. For the NAT2 slow acetylator genotypes, the NAT2*5/*7 diplotype was found to have a 7-fold increased risk to develop bladder cancer (OR = 7.14; 95% CI: 1.30-51.41). However, in tobacco consumers, we have shown that Null GSTM1, Wild GSTT1, Slow NAT2, XPC (CC) and XPG (CC) are genetic risk factors for the disease. When combined together in susceptible individuals compared to protected individuals these risk factors give an elevated OR (OR = 61). So, we have shown a strong cumulative effect of tobacco and different combinations of studied genetic risk factors which lead to a great susceptibility to bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21647780     DOI: 10.1007/s12253-011-9398-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  46 in total

1.  GSTT1-null genotype is a protective factor against bladder cancer.

Authors:  Wun-Jae Kim; Heon Kim; Cheol-Hwan Kim; Moo-Song Lee; Bong Ryoul Oh; Hyun Moo Lee; Takahiko Katoh
Journal:  Urology       Date:  2002-11       Impact factor: 2.649

2.  A multiplex polymerase chain reaction protocol for the simultaneous analysis of the glutathione S-transferase GSTM1 and GSTT1 polymorphisms.

Authors:  M Arand; R Mühlbauer; J Hengstler; E Jäger; J Fuchs; L Winkler; F Oesch
Journal:  Anal Biochem       Date:  1996-04-05       Impact factor: 3.365

Review 3.  Epidemiology and etiology of bladder cancer.

Authors:  S M Cohen; S L Johansson
Journal:  Urol Clin North Am       Date:  1992-08       Impact factor: 2.241

4.  Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1.

Authors:  A J Fretland; M A Doll; M A Leff; D W Hein
Journal:  Pharmacogenetics       Date:  2001-08

5.  GSTM1 and GSTT1 genes are potential risk modifiers for bladder cancer.

Authors:  S Z Abdel-Rahman; W A Anwar; W E Abdel-Aal; H M Mostafa; W W Au
Journal:  Cancer Detect Prev       Date:  1998

6.  Polymorphisms in XPD, XPC and the risk of death in patients with urinary bladder neoplasms.

Authors:  Somali Sanyal; Petra J De Verdier; Gunnar Steineck; Per Larsson; Erik Onelöv; Kari Hemminki; Rajiv Kumar
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

7.  The T341C (Ile114Thr) polymorphism of N-acetyltransferase 2 yields slow acetylator phenotype by enhanced protein degradation.

Authors:  Yu Zang; Shuang Zhao; Mark A Doll; J Christopher States; David W Hein
Journal:  Pharmacogenetics       Date:  2004-11

8.  [Relationship between genetic polymorphism of NAT2 and susceptibility to urinary bladder cancer].

Authors:  Gang-yue Hao; Wei-dong Zhang; Yong-he Chen; Dao-xin Zhang; Yu-hai Zhang
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2004-05

Review 9.  Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review.

Authors:  H Raunio; K Husgafvel-Pursiainen; S Anttila; E Hietanen; A Hirvonen; O Pelkonen
Journal:  Gene       Date:  1995-06-14       Impact factor: 3.688

10.  Mutagen sensitivity and genetic variants in nucleotide excision repair pathway: genotype-phenotype correlation.

Authors:  Jie Lin; Gary E Swan; Peter G Shields; Neal L Benowitz; Jian Gu; Christopher I Amos; Mariza de Andrade; Margaret R Spitz; Xifeng Wu
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-10       Impact factor: 4.254

View more
  23 in total

Review 1.  Quantitative assessment of the association between XPG Asp1104His polymorphism and bladder cancer risk.

Authors:  Chuan Liu; Qinghua Yin; Jianbing Hu; Jie Weng; Yajie Wang
Journal:  Tumour Biol       Date:  2013-09-06

2.  Combined effect of tobacco and DNA repair genes polymorphisms of XRCC1 and XRCC2 influence high risk of head and neck squamous cell carcinoma in northeast Indian population.

Authors:  Javed Hussain Choudhury; Biswadeep Choudhury; Sharbadeb Kundu; Sankar Kumar Ghosh
Journal:  Med Oncol       Date:  2014-06-24       Impact factor: 3.064

3.  Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.

Authors:  Kang Sun; Aixia Gong; Pin Liang
Journal:  Tumour Biol       Date:  2014-10-30

4.  Complex association between ERCC2 gene polymorphisms, gender, smoking and the susceptibility to bladder cancer: a meta-analysis.

Authors:  Yuanyi Wu; Yong Yang
Journal:  Tumour Biol       Date:  2014-02-07

5.  Expression of XPG protein in human normal and tumor tissues.

Authors:  Miguel Aracil; Lisa M Dauffenbach; Marta Martínez Diez; Rana Richeh; Victoria Moneo; Juan Fernando Martínez Leal; Luis Francisco García Fernández; Christopher A Kerfoot; Carlos M Galmarini
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

6.  XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis.

Authors:  Qiang-Sheng Dai; Rui-Xi Hua; Rui-Fang Zeng; Jian-Ting Long; Zhen-Wei Peng
Journal:  Tumour Biol       Date:  2013-08-06

7.  Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis.

Authors:  Su-Xia Li; Qiang-Sheng Dai; Su-Xiu Chen; Shao-Dan Zhang; Xiao-Yu Liao; Xia Deng; Hong-Bo Chi; Feng-Jie Li; Jin-Hong Zhu; Yi-Yan Jiang
Journal:  Tumour Biol       Date:  2013-12-18

8.  An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis.

Authors:  Yan Zhang; Xinhua Wang; Wei Zhang; Shengkai Gong
Journal:  Tumour Biol       Date:  2012-12-27

9.  Multiple analytical approaches reveal distinct gene-environment interactions in smokers and non smokers in lung cancer.

Authors:  Rakhshan Ihsan; Pradeep Singh Chauhan; Ashwani Kumar Mishra; Dhirendra Singh Yadav; Mishi Kaushal; Jagannath Dev Sharma; Eric Zomawia; Yogesh Verma; Sujala Kapur; Sunita Saxena
Journal:  PLoS One       Date:  2011-12-19       Impact factor: 3.240

10.  Association between the ERCC5 Asp1104His polymorphism and cancer risk: a meta-analysis.

Authors:  Mei-Ling Zhu; Mengyun Wang; Zhi-Gang Cao; Jing He; Ting-Yan Shi; Kai-Qin Xia; Li-Xin Qiu; Qing-Yi Wei
Journal:  PLoS One       Date:  2012-07-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.